Arthur M. Friedlander

13.2k citations

109 papers · 9.2k indexed · 5 hit papers · h-index 50

Impact in

Virology top 0.5%
- Poxvirus research and outbreaks
Genetics top 0.1%
- Yersinia bacterium, plague, ectoparasites research
- Bacterial Genetics and Biotechnology

Papers in

Genetics 54
- Yersinia bacterium, plague, ectoparasites research 30
- Bacterial Genetics and Biotechnology 26
Virology 8

Co-authors: Susan L. Welkos Edward M. Eitzen Stephen F. Little Joseph E. McDade Jerome Hauer Gerald Parker Michael T. Osterholm Trish M. Perl
Journals: Infection and Immunity (22 papers)Vaccine (12 papers)Microbial Pathogenesis (7 papers)Journal of Biological Chemistry (5 papers)The Journal of Infectious Diseases (5 papers)
Partner nations: United States United Kingdom Israel

In The Last Decade

Arthur M. Friedlander

106 papers receiving 8.8k citations

Hit Papers

5 papers align trajectories log scale

Anthrax as a Biological Weapon, 2002 2002 · 729 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 JAMA
2001 JAMA
2000 JAMA
1999 JAMA
1986 Journal of Biological Chemistry

Peers

Countries citing papers authored by Arthur M. Friedlander

Since Specialization

Citations

This map shows the geographic impact of Arthur M. Friedlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur M. Friedlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur M. Friedlander more than expected).

Fields of papers citing papers by Arthur M. Friedlander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur M. Friedlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur M. Friedlander. The network helps show where Arthur M. Friedlander may publish in the future.

Co-authors

The 25 scholars most cited alongside Arthur M. Friedlander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur M. Friedlander Line = papers co-authored together Arthur M. Friedlander links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models PLoS neglected tropical diseases ·I. Mijakovic, Andrew P. Bluhm, Donald J. Chabot, Arthur M. Friedlander, Richard A. Bowen, Ben CRAWFORD, Ted L. Hadfield, Airn E. Hartwig, Jason K. Blackburn, Michael H. Norris	2024	0
2	Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine Vaccine ·Donald J. Chabot, Wilson J. Ribot, Joseph G. Joyce, James C. Cook, Robert W. Hepler, Debbie Nahas, Jennifer Chua, Arthur M. Friedlander	2016	11
3	Localization and structural analysis of a conserved pyruvylated epitope in Bacillus anthracis secondary cell wall polysaccharides and characterization of the galactose-deficient wall polysaccharide from avirulent B. anthracis CDC 684 Glycobiology ·Lennart S. Forsberg, T. G. Abshire, Arthur M. Friedlander, Conrad P. Quinn, Elmar L. Kannenberg, Russell W. Carlson	2012	39
4	Capsule depolymerase overexpression reduces Bacillus anthracis virulence Microbiology ·Angelo Scorpio, Donald J. Chabot, William Alan Day, Timothy A. Hoover, Arthur M. Friedlander	2010	22
5	Advances in the development of next-generation anthrax vaccines Vaccine ·Arthur M. Friedlander, Stephen F. Little	2009	57
6	A Short Course of Antibiotic Treatment Is Effective in Preventing Death from Experimental Inhalational Anthrax after Discontinuing Antibiotics The Journal of Infectious Diseases ·Nicholas J. Vietri, Bret K. Purcell, Rose K E N N E D, Zhongyun Hua, Elizabeth K. Leffel, Nancy Twenhafel, Bruce E. Ivins, Mark D. Kellogg, W.M. Webster, Mary E. Wright, Arthur M. Friedlander	2008	23
7	The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection Bioorganic & Medicinal Chemistry Letters ·Yusheng Xiong, Judyann Wiltsie, Andrea Woods, Jianxiong Guo, James V. Pivnichny, Wei Tang, Alka Bansal, Richard Cummings, Barry R. Cunningham, Arthur M. Friedlander, Cameron Douglas, Scott P. Salowe, Dennis M. Zaller, Edward M. Scolnick, Dennis M. Schmatz, Kenneth F. Bartizal, Jeffrey D. Hermes, Malcolm MacCoss, Kevin T. Chapman	2005	44
8	The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence Microbial Pathogenesis ·Itai Mendelson, Adriana Leite de Almeida Souza, Angelo Scorpio, Joel A. Bozue, Avigdor Shafferman, Arthur M. Friedlander	2004	22
9	Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague Vaccine ·Susan L. Welkos, M. Louise M. Pitt, Mark Martinez, Arthur M. Friedlander, Peter Vogel, Ralph F. Tammariello	2002	83
10	Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans Vaccine ·Phillip R. Pittman, Astrea Rossetti, Dominique Pifat, Kevin Coonan, Paul Gibbs, S F Little, Leslie D. Harrison, Robert A. Myers, Gerald W. Parker, Arthur M. Friedlander	2002	107
11	Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid Vaccine ·Phillip R. Pittman, حیدر علی شایانفر, Joseph A. Mangiafico, Paul Gibbs, Kelly T. McKee, Arthur M. Friedlander, Maria H. Sjögren	2002	27
12	Anthrax vaccine: short-term safety experience in humans Vaccine ·Phillip R. Pittman, Paul Gibbs, Timothy Lewis Cannon, Arthur M. Friedlander	2001	91
13	Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin Vaccine ·Patricia Fellows, Patrick M. Carter, Bruce E. Ivins, M. Louise M. Pitt, Cynthia A. Rossi, Paul Gibbs, Arthur M. Friedlander	2001	159
14	Tularemia as a Biological Weapon JAMA ·David T. Dennis, Thomas V. Inglesby, Gustavo ívila Dias, John G. Bartlett, Michael S. Ascher, Edward M. Eitzen, Anne D. Fine, Arthur M. Friedlander, Jerome Hauer, Marcelle Layton, Scott R. Lillibridge, Joseph E. McDade, Michael T. Osterholm, Tara O’Toole, Gerald Parker, Trish M. Perl, Philip K. Russell, Kevin Tonat, Mouhamed Diouf Hit paper breakdown →	2001	1020
15	Plague as a Biological Weapon JAMA ·Thomas V. Inglesby, David T. Dennis, Donald A. Henderson, John G. Bartlett, Michael S. Ascher, Edward M. Eitzen, Anne D. Fine, Arthur M. Friedlander, Jerome Hauer, John F. Koerner, Marcelle Layton, Joseph E. McDade, Michael T. Osterholm, А.Ю. Тетерин, Gerald Parker, Trish M. Perl, Philip K. Russell, Monica Schoch‐Spana, Kevin Tonat, Mouhamed Diouf Hit paper breakdown →	2000	708
16	Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans Vaccine ·Phillip R. Pittman, Joseph A. Mangiafico, Cynthia A. Rossi, Timothy Lewis Cannon, Paul Gibbs, Gerald W. Parker, Arthur M. Friedlander	2000	45
17	V antigen ofYersinia pestisinhibits neutrophil chemotaxis Microbial Pathogenesis ·Susan L. Welkos, Arthur M. Friedlander, D.A. McDowell, W. Ruitenbeek, Rose K E N N E D	1998	49
18	Anthrax as a Potential Biological Warfare Agent Archives of Internal Medicine ·James C. Pile, John D. Malone, Edward M. Eitzen, Arthur M. Friedlander	1998	133
19	Studies on the role of plasminogen activator in systemic infection by virulentYersinia pestisstrain C092 Microbial Pathogenesis ·Susan L. Welkos, Arthur M. Friedlander, Kelly J. Davis	1997	100
20	Development Of A Live, Oral, Attenuated Vaccine Against El Tor Cholera The Journal of Infectious Diseases ·David N. Taylor, Kevin Killeen, حیدر علی شایانفر, Julie Kenner, Trinka S. Coster, David T. Beattie, J W Ezzell, Amanda Ciofu, Andrew F. Trofa, Maria H. Sjögren, Arthur M. Friedlander, John J. Mekalanos, Jerald Sadoff	1994	88

About Arthur M. Friedlander

Arthur M. Friedlander is a scholar working on Genetics, Virology, Parasitology, Infectious Diseases and Pharmacology, having authored 109 papers that have together received 9.2k indexed citations. Recurring topics across this work include Bacillus and Francisella bacterial research (74 papers), Yersinia bacterium, plague, ectoparasites research (30 papers), Bacterial Genetics and Biotechnology (26 papers), Bacteriophages and microbial interactions (23 papers), Viral Infections and Outbreaks Research (15 papers), Pharmacological Effects of Natural Compounds (10 papers), Viral gastroenteritis research and epidemiology (9 papers) and Vector-borne infectious diseases (8 papers). The work is most often cited by research in Virology (1.1k citations), Genetics (4.8k citations), Endocrinology (786 citations), Parasitology (822 citations) and Biotechnology (1.0k citations). Arthur M. Friedlander has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Susan L. Welkos, Edward M. Eitzen, Stephen F. Little, Joseph E. McDade, Jerome Hauer, Gerald Parker, Michael T. Osterholm, Trish M. Perl, Kevin Tonat and Thomas V. Inglesby. Their work appears in journals such as Infection and Immunity, Vaccine, Microbial Pathogenesis, Journal of Biological Chemistry and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact